In this article, we discuss the 5 stocks to buy before the next pandemic. If you wish to read our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 10 Stocks to Buy Before the Next Pandemic.
5. Moderna, Inc. (NASDAQ:MRNA)
Number of Hedge Fund Holders: 41
Moderna, Inc. (NASDAQ:MRNA) develops messenger RNA-based vaccines and therapies to treat infectious, cardiovascular, auto-immune and immuno-oncology diseases. It developed the SpikeVax Covid-19 vaccine, which is approved for usage by all major government regulators around the world. Moderna, Inc. (NASDAQ:MRNA) currently boasts 31 vaccine candidates in its drug pipeline, with 19 in clinical trials.
In late April, Moderna, Inc. (NASDAQ:MRNA) announced plans to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec, Canada, as part of a long-term strategic partnership with the Government of Canada to enhance pandemic preparedness. Piper Sandler analyst Edward Tenthoff on May 17 maintained an ‘Overweight’ rating on Moderna, Inc. (NASDAQ:MRNA) shares, and lowered the price target to $214 from $348 based on “pipeline adjustments reflecting current market conditions.”
For the quarter ending March, Moderna, Inc. (NASDAQ:MRNA) posted EPS of $8.58, exceeding estimates by $2.96. Revenue of $6.07 billion signaled growth of 213.16% from the year-ago quarter, and also beat forecasts by $1.64 billion.
41 hedge funds held stakes in Moderna, Inc. (NASDAQ:MRNA) at the close of the first quarter, down from 43 hedge funds a quarter earlier. The total value of Q1 hedge fund holdings stood at $3.79 billion.
Baillie Gifford, an investment firm, talked Moderna, Inc. (NASDAQ:MRNA) in its Q2 2021 investor letter. Here’s what the fund said:
“Among the top contributors to Fund performance in the second quarter was Moderna. Moderna, Inc. (NASDAQ:MRNA) has just reported its first profitable quarter in the company’s history – net income for the most recent quarter was $1.2 billion. It reported revenue of $1.9 billion, an impressive increase compared to $8 million a year ago, driven by the sales of its Covid-19 vaccine. Moderna, Inc. (NASDAQ:MRNA) is expecting to deliver up to 1 billion vaccine doses in 2021 and is in discussions to increase global supply to governments around the world. Our long-term focus remains on the transformational potential of Moderna’s technology and its ability to address different diseases.”